TH91886B - The use of CB1 inhibitors to treat the adverse effects and food adverse effects of schizophrenia. - Google Patents
The use of CB1 inhibitors to treat the adverse effects and food adverse effects of schizophrenia.Info
- Publication number
- TH91886B TH91886B TH601006106A TH0601006106A TH91886B TH 91886 B TH91886 B TH 91886B TH 601006106 A TH601006106 A TH 601006106A TH 0601006106 A TH0601006106 A TH 0601006106A TH 91886 B TH91886 B TH 91886B
- Authority
- TH
- Thailand
- Prior art keywords
- schizophrenia
- adverse effects
- patients
- inhibitors
- treat
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title abstract 3
- 230000002411 adverse Effects 0.000 title 2
- 230000000694 effects Effects 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract 4
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims abstract 2
- 208000010877 cognitive disease Diseases 0.000 claims abstract 2
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000000379 schizophrenia 2 Diseases 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Abstract
การประดิษฐ์นี้เปิดเผย และอ้างถึงรูปแบบการรักษาภาวะบกพร่องความรู้ความเข้าใจ ใน ผู้ป่วยที่เจ็บป่วยจากอาการจิตเภท โดยการให้สารต้านตัวรับ CB1 ตามที่ได้อธิบายไว้ในที่นี้แก้ผู้ป่วย ดังกล่าว ในปริมาณที่ให้ประสิทธิภาพทางการรักษา ในอีกลักษณะหนึ่ง การประดิษฐ์นี้ยังเปิดเผย และ อ้างถึงการใช้ร่วมกันของสารต้านตัวรับ CB1 หนึ่งชนิดหรือมากกว่า กับสารออกฤทธิ์ทางจิตเวชหนึ่ง ชนิดหรือมากกว่า ซึ่งเป็นประโยชน์ในการรักษาความผิดปกติด้านจิตเวช การใช้ร่วมกันของสาร ประดิษฐ์นี้ส่งผลเสริมฤทธิ์กัน โดยที่การใช้ร่วมกันของสารนี้จะส่งผลในการปรับสภาพอาการที่ ต้องการ และอาการไม่พึงประสงค์ของภาวะจิตเภท การเพิ่มขึ้นของน้ำหนักตัว และภาวะภวังค์ This invention revealed And refer to a treatment model for cognitive impairment in patients with schizophrenia. By administering a CB1 receptor antagonist as described here, correct such patients at therapeutic efficacy doses. In another way The invention also discloses and refers to the combined use of one or more CB1 receptor antagonists. With one psychoactive substance Type or more Which is useful in treating psychiatric disorders Combination of substances This invention resulted in synergistic effects. Where the combined use of this substance results in the conditioning of the desired symptoms and the adverse reactions of schizophrenia. Weight gain And reverie
Claims (2)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH91886B true TH91886B (en) | 2008-10-20 |
| TH91886A TH91886A (en) | 2008-10-20 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA025086B9 (en) | INDOLAMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| EA201000341A1 (en) | 2-ANILINOPURIN-8-ONE AS TTK / MPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| MX2008013836A (en) | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
| BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| BRPI0820112B8 (en) | isoxazole-pyridine derivatives, their use and preparation and drug processes | |
| TW200635899A (en) | Chemical compounds | |
| MX2009004908A (en) | Chemical compounds. | |
| MX2008013212A (en) | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors. | |
| UA103272C2 (en) | 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS$ 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR INHIBITORS OR BACE2 | |
| EA201391786A1 (en) | HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS | |
| NO20070566L (en) | Azine carboxamides as an anticancer agent | |
| NO20070199L (en) | Substituted quinazolones as anti-cancer agents | |
| TW200634003A (en) | Chemical compounds | |
| MX2007008924A (en) | Chemical compounds. | |
| EA201391752A1 (en) | SPYRO- [1,3] -OXAZINS AND SPYRO- [1,4] -OXAZEPINS AS BACE1 AND / OR BACE2 INHIBITORS | |
| EA200701296A1 (en) | 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| WO2007071963A3 (en) | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | |
| NO20083758L (en) | New therapeutic combinations for the treatment of depression | |
| DE602006003432D1 (en) | LATORS OF THE ANDROGEN RECEPTOR | |
| EA200971107A1 (en) | CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease | |
| BRPI0418099A (en) | compounds, pharmaceutical composition, and use of a compound | |
| EA200802007A1 (en) | COMPOUNDS POTENTIATING AMPA RECEPTOR AND APPLICATION OF THE SPECIFIED COMPOUNDS IN MEDICINE | |
| BR112014006763A2 (en) | n- (3- (2-amino-6,6-difluoro-4,4a, 5,6,7,7a-hexahydro-cyclopenta [e] [1,3] oxazin-4-yl) -phenyl) -amides as bace1 inhibitors |